Get started
Author

José Carlos Tapia

Observed names: J Carlos Tapia-Tapia, J. Carlos Tapia, J. Tapia, J.C. Tapia, Jose C. Tapia, Jose C. Tapia, Jose Carlos, Jose Carlos Tapia, Jose Carlos Tapia Tapia, Jose Tapia, Tapia, Jose, Tapia, Jose Carlos
Observed institutions: Universitat Autònoma de Barcelona, University of Toronto, Universidad Peruana Cayetano Heredia, Universidad de San Martín de Porres, Barts Health NHS Trust, Velindre NHS Trust, Hospital de Sant Pau, Institut Gustave Roussy, Hospital Clínic de Barcelona, National Health Service Wales, Velindre Cancer Centre
ORCID: 0000-0001-6545-8862
Observed ORCID: 0000-0001-6545-8862
OpenAlex ID: A5048190384
World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis
2020 · Maria Lazo-Porras, Gabriela J. Prutsky, et al. · BMC Infectious Diseases · 51
PDF
Hair follicle characteristics as early marker of Type 2 Diabetes
2016 · J. Jaime Miranda, Alvaro Taype-Rondan, et al. · Medical Hypotheses · 29
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
2024 · Francesco Massari, Matteo Santoni, et al. · Cancer Immunology Immunotherapy · 16
PDF
NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
2024 · Matthew Young, Jose C. Tapia, et al. · Clinical Genitourinary Cancer · 13
PDF
What About Variant Histologies in Bladder Cancer?
2024 · Elizabeth Day, Javier Gavira, et al. · European Urology Focus · 10
Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period
2021 · Aida Bujosa, Consolación Moltó, et al. · Journal of the National Comprehensive Cancer Network · 10
Las deficiencias en la presentación de los estudios transversales de acuerdo con la declaración STROBE: el caso del síndrome metabólico en adultos de Perú
2015 · Jose Carlos Tapia, Eloy F Ruiz, et al. · Colombia medica · 10
PDF
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
2023 · Matteo Santoni, Francesco Massari, et al. · Clinical and Experimental Medicine · 9
PDF
Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT)
2025 · Javier Gavira, Edouard Auclin, et al. · European Journal of Cancer · 6
World Health Organization (WHO) Antibiotic Regimen Against Other Regimens for the Treatment of Leprosy: A Systematic Review and Meta-Analysis
2018 · Maria Lazo-Porras, Gabriela J. Prutski, et al. · SSRN Electronic Journal · 6
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
2024 · Mimma Rizzo, Andrey Soares, et al. · Scientific Reports · 5
PDF
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset
2025 · Alessandro Rizzo, Anas Zayed, et al. · Clinical & Experimental Metastasis · 4
Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations
2026 · Sara Elena Rebuzzi, Aruni Ghose, et al. · The Oncologist · 3
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
2025 · Lorena Incorvaia, Sarah Scagliarini, et al. · Scientific Reports · 3
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021
2024 · Jose C. Tapia, Freya Bosma, et al. · Clinical Genitourinary Cancer · 3
Treatment satisfaction and need for shared decision‐making in patients with psoriasis from Peru
2017 · J.C. Tapia, K. Chavez, et al. · British Journal of Dermatology · 3
Association between control group therapy and magnitude of clinical benefit of cancer drugs
2022 · Consolacion Molto, Ariadna Tibau, et al. · Scientific Reports · 2
PDF
Ninety‐day mortality and clinical outcomes of patients with solid tumours and COVID ‐19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study
2021 · Jose Carlos Tapia, Javier Gavira, et al. · International Journal of Cancer · 2
1719P Clinical characteristics and 28-day mortality among patients with solid cancers and COVID-19 in a tertiary hospital
2020 · J.C. Tapia, J. Gavira, et al. · Annals of Oncology · 2
PDF
The dream of health information for all
2016 · Alvaro Proaño, Eloy F Ruiz, et al. · F1000Research · 2
PDF
Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: A UK Multi-Centre Retrospective Study
2026 · Benjamin Thomas Crosby, Steffanie Winsor, et al. · Clinical Genitourinary Cancer · 1
P-278 Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC)
2023 · A. Romano, J. Gavira, et al. · Annals of Oncology · 1
PDF
The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.
2022 · Elia Seguí, Edouard Auclin, et al. · Journal of Clinical Oncology · 1
1585MO Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies
2020 · A. Bujosa Rodríguez, C. Molto Valiente, et al. · Annals of Oncology · 1
PDF
Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015
2019 · A Bujosa Rodríguez, J.C. Tapia, et al. · Annals of Oncology · 1
PDF
Works count: 67
Citation count: 196
H-index: 8
I10-index: 7
Year
Topic
Type